Latest Intelligence on Pharmaceuticals in Brazil

Published within

« | 1 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

HIV patents: no solution - yet

While the WTO has not yet made a breakthrough on the issue of patent-free HIV drugs for developing economies, something must be done to alleviate the human and economic cost of the HIV epidemic. Western pharma companies will inevitably lose out - the only question is how well their profit maintenance strategies can cushion the blow.

Published By Datamonitor
22 Oct 2002
CommentWire
CommentWire

HIV drugs: patent disputes escalate

Published By Datamonitor
28 Aug 2001
CommentWire
CommentWire

GSK: another price-reduction deal in emerging markets

As part of its ongoing attempts to penetrate the emerging markets, GlaxoSmithKline has signed an innovative pneumococcal vaccines deal in Brazil, which also includes a technology transfer and R&D investment. As well as boosting the pharma giant's volume in this rapidly growing and commercially attractive market, the deal is expected to increase access to vaccines in the country.

Published By Datamonitor
29 Sep 2009
CommentWire
CommentWire

GlaxoSmithKline: cutting the cost of HIV drugs

GlaxoSmithKline's fifth round of price cuts since 1997 includes 14 HIV drugs reduced by an average of 21%. The biggest reduction is a 40% cut in the price of Ziagen, a first and second line AIDS treatment. With the use of compulsory licenses becoming more frequent among developing countries, GSK will hope that such price cuts appease governments and prevent their patents being bypassed.

Published By Datamonitor
21 Feb 2008
Expert View
Expert View

Brazilian patent threat poses challenge to big pharma

Relying on its reputation as a world leader in HIV/AIDS drug pricing negotiations, Brazil is threatening to disregard patents unless Abbott Laboratories, Gilead Sciences and Merck & Co. allow it to produce generic versions of their four leading AIDS drugs. Datamonitor's Mar Ferrero investigates the likely ramifications of such a move...

Published By Datamonitor
23 Jun 2005
CommentWire
CommentWire

Ache: Brazilian domestic player to step up its game

Ache, the Brazilian branded generics specialist, has announced its intention to pursue an initial public offering in order to raise capital and remain competitive. The move reflects the growing interest in Brazil's burgeoning pharmaceutical market, and is essential if Ache is to compete with the considerable growth in both domestic and international players in the country.

Published By Datamonitor
17 Nov 2010

« | 1 | » »|

No help is available.